The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S4-S13 , August 2007

Optimizing Treatment of Chronic Obstructive Pulmonary Disease: An Assessment of Current Therapies

  • Robert A. Wise, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Robert A. Wise, MD, Johns Hopkins University School of Medicine, Division of Pulmonary and Critical Care Medicine at the JHU Asthma and Allergy Center, 5501 Hopkins Bay View Circle, Room 4B.74, Baltimore, MD 21224.
    • ,
  • Donald P. Tashkin, MD

      Affiliations

    • Division of Pulmonary, Critical Care Medicine, and Hospitalists, David Geffen School of Medicine at UCLA, University of California–Los Angeles, Los Angeles, California, USA

References 

  1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ. 2002;51:1–16
  2. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249–259
  3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255–1259
  4. National Heart, Lung, and Blood Institute, National Institutes of Health. Chronic obstructive pulmonary disease data fact sheet. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.htm. Accessed June 23, 2006.
  5. Celli BR, MacNee W ATS/ERS Task Force Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. [published correction appears in Eur Respir J. 2006;27:242] Eur Respir J. 2004;23:932–946
  6. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Updated 2005: Executive Summary. Available at: http://www.goldcopd.com/Guidelineitem.asp?1=2&l2=1&intId=989. Accessed April 27, 2007.
  7. Agustí AGN. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:367–370
  8. Soriano JB, Visick GT, Muellerova H, Nassrin P, Hansell A. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107
  9. van Manen JGE, Bindels PJE, Dekker FW, et al. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol. 2003;56:1177–1184
  10. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report. National Heart, Lung, and Blood Institute, National Institutes of Health, US Dept of Health and Human Services, 2001. Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=1151. Accessed April 4, 2006.
  11. Anthonisen NR, Connett JE, Murray RP Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–679
  12. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–280
  13. Proventil. Kenilworth, NJ: Schering Corporation; 2004;[package insert]
  14. Volmax. Tewksbury, MA: Muro Pharmaceutical, Inc; 2001;[package insert]
  15. Maxair Autohaler. Northridge, CA: 3M Pharmaceuticals; 2003;[package insert]
  16. Xopenex. Marlborough, MA: Sepracor Inc; 2005;[package insert]
  17. Serevent Diskus. Research Triangle Park, NC: GlaxoSmithKline; 2006;[package insert]
  18. Foradil Aerolizer. Kenilworth, NJ: Schering Corporation; 2003;[package insert]
  19. Atrovent. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2006;[package insert]
  20. Spiriva Handihaler. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2005;[package insert]
  21. Combivent. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2005;[package insert]
  22. DuoNeb. Napa, CA: Dey; 2005;[package insert]
  23. Advair Diskus. Research Triangle Park, NC: GlaxoSmithKline; 2006;[package insert]
  24. Symbicort. Wilmington, DE: AstraZeneca LP; 2006;[package insert]
  25. ProAir HFA. Miami, FL: IVAX Laboratories, Inc; 2006;[package insert]
  26. Proventil HFA. Kenilworth, NJ: Schering Corporation; 2001;[package insert]
  27. Ventolin HFA. Research Triangle Park, NC: GlaxoSmithKline; 2005;[package insert]
  28. Xopenex HFA. Marlborough, MA: Sepracor Inc; 2005;[package insert]
  29. Atrovent HFA. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2006;[package insert]
  30. Sin DD, McAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease—scientific review. JAMA. 2003;290:2301–2312
  31. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327
  32. Vincken W, van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19:209–216
  33. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(2):CD002876
  34. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: β-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol. 2006;31:219–230
  35. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1:303–312
  36. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy—a systematic review and meta-analysis. Arch Intern Med. 1999;159:941–955
  37. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59–65
  38. Pulmicort. Wilmington, DE: AstraZeneca LP; 2004;[package insert]
  39. Qvar. Northridge, CA: 3M Pharmaceuticals; 2002;[package insert]
  40. Flovent Diskus. Research Triangle Park, NC: GlaxoSmithKline; 2005;[package insert]
  41. Flovent HFA. Research Triangle Park, NC: GlaxoSmithKline; 2006;[package insert]
  42. Azmacort. Cranbury, NJ: Kos Pharmaceuticals, Inc; 2004;[package insert]
  43. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4:253–262
  44. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  45. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ. 2005;330:640–644
  46. Brovana. Marlborough, MA: Sepracor Inc; 2006;[package insert]
  47. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest. 1994;105:1411–1419
  48. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–222
  49. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834–843
  50. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe COPD. Am J Respir Crit Care Med. 2007;175:144–149
  51. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398S–401S
  52. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117(suppl 2):380S–385S
  53. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163:1180–1186
  54. Ai-Ping C, Lee K-H, Lim T-K. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest. 2005;128:518–524
  55. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;274:1852–1857
  56. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345–1352
  57. Murata GH, Gorby MS, Chick TW, Halperin AK. Treatment of decompensated chronic obstructive pulmonary disease in the emergency department—correlation between clinical features and prognosis. Ann Emerg Med. 1991;20:125–129
  58. Miravitlles M, Ferrer M, Pont À, et al. IMPAC Study Group Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–395
  59. Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403
  60. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006;4:101–124
  61. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000;355:362–368
  62. Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. J Gen Intern Med. 2003;18:213–221
  63. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809–817
  64. Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006;82:431–443
  65. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2006. Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed January 31, 2007

PII: S0002-9343(07)00403-2

doi: 10.1016/j.amjmed.2007.04.007

The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S4-S13 , August 2007

Article Tools

* Image Usage & Resolution